Catalyst (CPRX) Down 2.5% Since Last Earnings Report: Can It Rebound?

Core Viewpoint - Catalyst Pharmaceuticals has shown resilience with a recent earnings report that exceeded expectations, indicating potential for continued growth despite some challenges in specific product lines [2][3][8]. Financial Performance - For Q4 2025, Catalyst reported adjusted earnings of 68 cents per share, surpassing the Zacks Consensus Estimate of 42 cents, although slightly down from 70 cents in the same quarter last year [2]. - Total revenues for the quarter reached $152.6 million, an 8% increase year over year, exceeding the Zacks Consensus Estimate of $140 million [3]. - Firdapse sales amounted to $97.6 million, reflecting an 18% year-over-year growth, driven by increased demand and prescription rates [4]. - Agamree generated revenues of $35.3 million, up 68% year over year, also beating estimates [5]. - Fycompa revenues were $19.6 million, down significantly year over year due to the introduction of generic competition, but still exceeded estimates [6]. Annual Results - For the full year 2025, Catalyst recorded total revenues of $589 million, a 20% increase year over year, and adjusted earnings per share of $2.72, surpassing the Zacks Consensus Estimate of $2.46 [8]. Future Guidance - For 2026, Catalyst expects total revenues between $615 million and $645 million, with Firdapse revenues projected between $435 million and $450 million, and Agamree revenues anticipated between $140 million and $150 million [9]. - Fycompa revenues are projected to be between $40 million and $45 million, despite the loss of patent exclusivity [10]. - R&D expenses are expected to be between $17.5 million and $22.5 million, with SG&A expenses anticipated to rise [11]. Market Reaction - Since the earnings release, there has been a 9.43% upward trend in consensus estimates, indicating positive market sentiment [12]. - Catalyst currently holds a Zacks Rank 1 (Strong Buy), suggesting expectations for above-average returns in the coming months [14]. Industry Context - Catalyst operates within the Zacks Medical - Drugs industry, where competitor Corcept Therapeutics has seen a 7.7% gain over the past month, although it faces challenges with a projected loss for the current quarter [15][16].